The Ohio State University pancreatic disorders network (OSU-PDN)

俄亥俄州立大学胰腺疾病网络 (OSU-PDN)

• 批准号: 9987079
• 负责人: DARWIN LEWIS CONWELL
• 金额: $ 28.83万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9987079
• 关键词: ANXA5 gene; Abdominal Pain; Address; Adult; Biological Markers; Blood; Brittle diabetes; Childhood; Clinical; Clinical Cancer Center; Clinical Research; Clinical Sciences; Collaborations; Consult; Development; Diabetes Mellitus; Diagnosis; Diagnostic; Digestive System Disorders; Disease; Disease Progression; Early Diagnosis; Fibrosis; Funding; Gastroenterologist; Gastroenterology; Goals; Individual; Inflammation; Institution; Knowledge; Left; Liquid substance; Main pancreatic duct; Malignant Neoplasms; Malignant neoplasm of pancreas; Malnutrition; Medical; Medical Research; Medical center; Methods; Modernization; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Insulin-Dependent Diabetes Mellitus; Ohio; Operative Surgical Procedures; Organ; Pancreas; Pancreatic Diseases; Pancreatic Polypeptide; Participant; Patient Triage; Patients; Pediatric Research; Peptides; Performance; Primary Care Physician; Proteins; Proteome; Proteomics; Protocols documentation; Publishing; Research; Research Infrastructure; Research Proposals; Resources; Risk; Secondary to; Serum; Services; Standardization; Testing; Translational Research; United States; United States National Institutes of Health; Universities; Urine; Validation; accurate diagnosis; base; biomarker panel; candidate marker; chronic pancreatitis; cohort; diagnostic biomarker; early detection biomarkers; pancreatic juice; programs; repository; research study; response; sample collection; translational study

Project Summary and Abstract (Initial Submission) The diagnosis of chronic pancreatitis and T3cDM remain two of the greatest challenges and unmet needs in modern gastroenterology. The focus of this U01 application from The Ohio State University is to form a strategic alliance among academic institutions in the United States. Our major goals are to address the research objectives and aims of the Consortium, and to be considered as a clinical center. Specifically, we a) describe The Ohio State University Pancreatic Disorders Network (OSU-PDN), b) propose two research studies for consideration by the Consortium and c) outline our clinical and translational research infrastructure. Several key experimental observations from our group in CP and T3cDM warrant confirmation [OSU- PDN] and validation [CSCPDPC-CCs] : 1) Proteomic analysis of pancreas fluid (PF) and urine (U) in CP subjects revealed statistically significant fold-changes in several pancreatic fluid proteins - SERPINA5, ANXA5, CST3 (candidate pancreatic fluid markers) and urine proteins - CPN2, A1AG1, AMYP (candidate urine markers) when compared to healthy controls and 2) A significant difference in serum pancreatic polypeptide response to a mixed meal was observed that may distinguish T3cDM from the much more prevalent T2DM. These preliminary observations are the focus of our research proposals for consideration by the Consortium Steering Committee. Our Clinical Center will be centrally coordinated by the Ohio State University Center for Clinical and Translational Science (CCTS/CTSA) in collaboration with other CTSAs from our “network partners” in the OSU-PDN and the Consortium. The CCTS/CTSA provides consulting services and access to clinical and translational research infrastructure. This unique resource will assist our team in communicating with the CDMC, DSMB and NIDDK central repository. Both research proposals from our network address gaps in knowledge and understanding of chronic pancreatitis, diabetes and pancreas cancer as outlined by the NIDDK- National Commission on Digestive Diseases, and are strategically aligned with the objectives of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC-CCs) (U01).

项目摘要和摘要（初次提交） 慢性胰腺炎和 T3cDM 的诊断仍然是两个最大的挑战， 现代胃肠病学中未满足的需求是俄亥俄州 U01 应用的重点。 州立大学旨在形成美国学术机构之间的战略联盟。 我们的主要目标是实现联盟的研究目标和目的，并 具体来说，我们 a) 描述俄亥俄州立大学 胰腺疾病网络 (OSU-PDN)，b) 提出两项研究供考虑 c) 概述我们的临床和转化研究基础设施。 我们小组在 CP 和 T3cDM 中的关键实验观察值得证实 [OSU- PDN] 和验证 [CSCPDPC-CCs]：1) 胰液 (PF) 和尿液的蛋白质组学分析 (U) 在 CP 受试者中揭示了几种胰液中显着的倍数变化 蛋白质 - SERPINA5、ANXA5、CST3（候选胰液标记物）和尿蛋白 - 与健康对照相比，CPN2、A1AG1、AMYP（候选尿液标记物）2) A 观察到血清胰多肽对混合膳食的反应存在显着差异 这可以将 T3cDM 与更为流行的 T2DM 区分开来。 观察结果是我们供联盟考虑的研究提案的重点 我们的临床中心将由俄亥俄州集中协调。 大学临床与转化科学中心 (CCTS/CTSA) 与 来自 OSU-PDN 和联盟中“网络合作伙伴”的其他 CTSA。 CCTS/CTSA 提供咨询服务以及临床和转化研究的机会 这一独特的资源将帮助我们的团队与 CDMC 进行沟通， DSMB 和 NIDDK 中央存储库均来自我们的网络地址差距。 对慢性胰腺炎、糖尿病和胰腺癌的了解和理解 由 NIDDK-国家消化疾病委员会概述，并战略性地 与慢性胰腺炎研究联盟的目标保持一致， 糖尿病和胰腺癌临床中心 (CSCPDPC-CC) (U01)。